Floatz Rating
BB66/100
Confidence
Indicative
Sponsor
OHSU Knight Cancer Institute
Modality
Small molecule
Development Phase
Phase 2/3
Status
Dormant
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
64High confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT03878524CT.gov Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME Trial | — | Terminated | — | — | — |
NCT03607643CT.gov A Study of the Efficacy of Cannabidiol in Patients With Multiple Myeloma, Glioblastoma Multiforme, and GI Malignancies | — | Unknown | — | — | — |
NCT01839487CT.gov PEGPH20 Plus Nab-Paclitaxel Plus Gemcitabine Compared With Nab-Paclitaxel Plus Gemcitabine in Participants With Stage IV Untreated Pancreatic Cancer | — | Completed | — | — | — |
NCT01065870CT.gov Neoadjuvant GTX With Chemoradiation for Pancreatic Cancer (Stage II/III) | — | Unknown | — | — | — |
NCT00720785CT.gov Natural Killer Cells and Bortezomib to Treat Cancer | — | Completed | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
73High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Malignant Pancreatic Neoplasm
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Dexasone (this asset) | OHSU Knight Cancer Institute | P2/3 | BB · 66 |
| Fluorouracilum | Jonsson Comprehensive Cancer Center | P4 | BBB |
| Metformin | State University of New York - Downstate Medical Center | P2 | BB |
| Irinotecan | Jonsson Comprehensive Cancer Center | P3 | BB |
| Oxaliplatin | Jonsson Comprehensive Cancer Center | P4 | BB |
| Immunoglobulin G1, Anti-(Humanized Mouse Monoclonal Hr3 .Beta.1 Chain Anti-Human Epidermal Growth Factor Receptor), Disulfide With Humanized Mouse Monoclonal Hr3 .Kappa.-Chain, Dimer | Chinese PLA General Hospital | P4 | BB |
| Cis-Diamminedichloroplatinum Ii | Jonsson Comprehensive Cancer Center | P2/3 | BB |
| S-1 | Ruijin Hospital | P4 | BB |
| Capecitabine | Tianjin Medical University Cancer Institute and Hospital | P4 | BB |
+42 more in the Malignant Pancreatic Neoplasm cohort
Other indications for Dexasone
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Chemotherapy-Induced Toxicity | — | P4 | BBB · 78 |
| Adult Acute Lymphoblastic Leukemia | — | P4 | BBB · 77 |
| B-Cell Childhood Acute Lymphoblastic Leukemia | — | P3 | BBB · 76 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
- FluorouracilumJonsson Comprehensive Cancer CenterBBB
- MetforminState University of New York - Downstate Medical CenterBB
- IrinotecanJonsson Comprehensive Cancer CenterBB
- OxaliplatinJonsson Comprehensive Cancer CenterBB
- Immunoglobulin G1, Anti-(Humanized Mouse Monoclonal Hr3 .Beta.1 Chain Anti-Human Epidermal Growth Factor Receptor), Disulfide With Humanized Mouse Monoclonal Hr3 .Kappa.-Chain, DimerChinese PLA General HospitalBB
Citation
Floatz Terminal. Dexasone in Malignant Pancreatic Neoplasm. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 14, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/dexasone-malignant-pancreatic-neoplasm
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →